![]() |
市场调查报告书
商品编码
1754047
导管直接血栓溶解装置市场报告(按输送方式、适应症(肺栓塞、深部静脉栓塞、中风等)、最终用户和地区划分)2025 年至 2033 年Catheter-Directed Thrombolysis Devices Market Report by Delivery Mode, Indication (Pulmonary Embolism, Deep Vein Thrombosis, Stroke, and Others), End User, and Region 2025-2033 |
2024年,全球导管式血栓溶解装置市场规模达3.944亿美元。展望未来, IMARC Group预计到2033年,该市场规模将达到5.916亿美元,2025-2033年期间的复合年增长率(CAGR)为4.61%。慢性病盛行率的不断上升、消费者对早期发现和治疗肺栓塞重要性的认识不断提高,以及医疗基础设施的显着改善,是推动市场发展的主要因素。
导管介入血栓溶解装置是用于治疗体内血管内血栓的先进医疗工具。这些装置专门设计用于将溶栓剂直接输送到血栓部位,在那里溶解阻塞物并恢復血流。此操作需要在影像引导下(例如X光或超音波检查),将一根细长的柔性导管插入受影响的血管。透过导管,溶栓药物直接输送到血栓部位或註入血栓周围的血管。导管介入血栓溶解已被证明能够快速恢復血流,降低长期併发症的风险,并保留受影响器官或肢体的功能。它常用于治疗深部静脉栓塞 (DVT)、肺栓塞、週边动脉闭塞和其他血管疾病。
The global catheter-directed thrombolysis devices market size reached USD 394.4 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 591.6 Million by 2033, exhibiting a growth rate (CAGR) of 4.61% during 2025-2033. The growing prevalence of chronic diseases, the rising consumer awareness about the importance of early detection and treatment of pulmonary embolism, and significant improvements in the healthcare infrastructure are some of the major factors propelling the market.
Catheter-directed thrombolysis devices are advanced medical tools used to treat blood clots that form within the body's blood vessels. These devices are specifically designed to deliver thrombolytic agents directly to the site of the clot, where they work to dissolve the obstruction and restore blood flow. The procedure involves the insertion of a catheter, a thin, flexible tube, into the affected blood vessel under image guidance, such as an X-ray or ultrasound. Through the catheter, a clot-dissolving medication is delivered directly to the clot or infused into the blood vessel surrounding it. Catheter-directed thrombolysis has proven to be highly effective in quickly restoring blood flow, reducing the risk of long-term complications, and preserving the functionality of the affected organ or limb. It is commonly used to treat conditions, such as deep vein thrombosis (DVT), pulmonary embolism, peripheral arterial occlusions, and other vascular disorders.
Directly delivering thrombolytic agents to the blood clot is a significant delivery mode in catheter-directed thrombolysis. In this approach, the catheter is inserted directly into the blood vessel where the clot is located, ensuring precise and targeted administration of the thrombolytic medication. This method allows for a concentrated and localized action, effectively dissolving the clot and restoring blood flow without affecting other parts of the circulatory system.
On the other hand, the positioning of a medical device at the clot site is a delivery mode in catheter-directed thrombolysis. These devices may include mechanical thrombectomy devices, such as rotating catheters or aspiration systems. This delivery mode is particularly beneficial in cases where direct infusion of thrombolytic agents may not be suitable, such as in large or resistant clots, or when the risk of bleeding from medication is a concern.
Pulmonary embolism is a critical medical condition and a leading indication segment in the catheter-directed thrombolysis market. PE occurs when a blood clot, often originating from deep veins in the legs, travels through the bloodstream and lodges in the arteries of the lungs, causing a potentially life-threatening obstruction. Catheter-directed thrombolysis is a highly effective treatment for PE as it rapidly dissolves the clot and restores blood flow to the lungs.
On the other hand, deep vein thrombosis is another major indication segment in the catheter-directed thrombolysis market. DVT occurs when a blood clot forms in a deep vein, most commonly in the legs. Catheter-directed thrombolysis for DVT not only alleviates symptoms and reduces the risk of severe complications but also plays a crucial role in preventing long-term issues, such as chronic venous insufficiency. As DVT is a prevalent and potentially serious condition, the demand for catheter-directed thrombolysis devices remains high in the market.
Hospitals represent the leading market segment
Hospitals serve as central hubs for medical care and are equipped with advanced facilities, skilled healthcare professionals, and specialized departments, making them ideal settings for performing catheter-directed thrombolysis procedures. The complexity and critical nature of vascular diseases and thrombotic disorders often require a multidisciplinary approach involving interventional radiologists, vascular surgeons, cardiologists, and other medical specialists available in a hospital environment. These medical professionals collaborate to diagnose and treat patients with conditions, including pulmonary embolism, deep vein thrombosis, peripheral arterial occlusions, and other vascular obstructions. Moreover, hospitals have access to state-of-the-art imaging technologies, such as fluoroscopy, ultrasound, and computed tomography (CT), which aid in precise catheter navigation and real-time visualization of the clot during the procedure. Additionally, hospitals maintain a comprehensive range of medical equipment and devices, including the latest catheter-directed thrombolysis technologies, to ensure optimal patient care.
North America exhibits a clear dominance in the market
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (United States and Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Russia and the rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, Indonesia and rest of Asia-Pacific), Latin America (Brazil, Mexico and rest of Latin America) and the Middle East and Africa. According to the report, North America represents the leading market.
The market in North America is primarily being driven due to advanced healthcare infrastructure, a well-established medical device industry, and a high prevalence of vascular diseases in the region. The region's strong emphasis on healthcare research and innovation has led to the development of cutting-edge catheter-directed thrombolysis devices, further driving their adoption.
The market in Asia Pacific is witnessing an increase in the aging population, which is more susceptible to vascular conditions, further augmenting the demand for these devices. The presence of leading medical device manufacturers and ongoing research and development efforts also contribute to the growth of the market in the Asia Pacific. With a combination of a vast patient pool, improving healthcare facilities, and a focus on technological advancements, the Asia Pacific region is expected to maintain its dominant position in the catheter-directed thrombolysis devices market.
Companies in the market are heavily investing in research and development to improve the design, efficacy, and safety of their catheter-directed thrombolysis devices. They are focused on creating innovative technologies and drug delivery mechanisms to enhance the clot-dissolving process and minimize the risk of bleeding complications. Moreover, leading players are conducting clinical trials to gather evidence of safety and efficacy and obtaining regulatory approvals from health authorities to market their devices globally. These processes helped establish the credibility and compliance of their products. Additionally, several companies are providing training and educational programs to healthcare professionals to ensure they had the necessary skills and knowledge to use catheter-directed thrombolysis devices effectively and safely. To stay competitive, major companies are launching new catheter-directed thrombolysis devices or upgraded existing ones. These products were often designed to be more user-friendly, precise, and capable of achieving better patient outcomes.